US representatives Kurt Schrader and Adam Kinzinger recently introduced the bipartisan Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, garnering support from the Association for Accessible medicines and a group of organizations representing patients, employers, taxpayers, providers, communities of color and consumer groups.
The AAM noted that “under Medicare Part B, health care providers are reimbursed the average sales price of the brand-name...